526 related articles for article (PubMed ID: 18325866)
1. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells.
Coxon FP; Thompson K; Roelofs AJ; Ebetino FH; Rogers MJ
Bone; 2008 May; 42(5):848-60. PubMed ID: 18325866
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases.
Dunford JE; Rogers MJ; Ebetino FH; Phipps RJ; Coxon FP
J Bone Miner Res; 2006 May; 21(5):684-94. PubMed ID: 16734383
[TBL] [Abstract][Full Text] [Related]
3. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro.
Idris AI; Rojas J; Greig IR; Van't Hof RJ; Ralston SH
Calcif Tissue Int; 2008 Mar; 82(3):191-201. PubMed ID: 18259679
[TBL] [Abstract][Full Text] [Related]
4. Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo.
Coxon FP; Ebetino FH; Mules EH; Seabra MC; McKenna CE; Rogers MJ
Bone; 2005 Sep; 37(3):349-58. PubMed ID: 16006204
[TBL] [Abstract][Full Text] [Related]
5. Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis.
Thompson K; Rogers MJ; Coxon FP; Crockett JC
Mol Pharmacol; 2006 May; 69(5):1624-32. PubMed ID: 16501031
[TBL] [Abstract][Full Text] [Related]
6. Alendronate promotes bone formation by inhibiting protein prenylation in osteoblasts in rat tooth replantation model.
Komatsu K; Shimada A; Shibata T; Wada S; Ideno H; Nakashima K; Amizuka N; Noda M; Nifuji A
J Endocrinol; 2013 Nov; 219(2):145-58. PubMed ID: 24096963
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonates: the first 40 years.
Russell RG
Bone; 2011 Jul; 49(1):2-19. PubMed ID: 21555003
[TBL] [Abstract][Full Text] [Related]
8. Nitrogen-containing bisphosphonate mechanism of action.
Reszka AA; Rodan GA
Mini Rev Med Chem; 2004 Sep; 4(7):711-9. PubMed ID: 15379639
[TBL] [Abstract][Full Text] [Related]
9. Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo.
Roelofs AJ; Coxon FP; Ebetino FH; Lundy MW; Henneman ZJ; Nancollas GH; Sun S; Blazewska KM; Bala JL; Kashemirov BA; Khalid AB; McKenna CE; Rogers MJ
J Bone Miner Res; 2010 Mar; 25(3):606-16. PubMed ID: 20422624
[TBL] [Abstract][Full Text] [Related]
10. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.
Coxon FP; Helfrich MH; Van't Hof R; Sebti S; Ralston SH; Hamilton A; Rogers MJ
J Bone Miner Res; 2000 Aug; 15(8):1467-76. PubMed ID: 10934645
[TBL] [Abstract][Full Text] [Related]
11. Morphological assessment of basic multicellular unit resorption parameters in dogs shows additional mechanisms of bisphosphonate effects on bone.
Allen MR; Erickson AM; Wang X; Burr DB; Martin RB; Hazelwood SJ
Calcif Tissue Int; 2010 Jan; 86(1):67-71. PubMed ID: 19953232
[TBL] [Abstract][Full Text] [Related]
12. Osteoclasts but not osteoblasts are affected by a calcified surface treated with zoledronic acid in vitro.
Schindeler A; Little DG
Biochem Biophys Res Commun; 2005 Dec; 338(2):710-6. PubMed ID: 16243296
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer cells inhibit spontaneous and bisphosphonate-induced osteoclast apoptosis.
Hussein O; Tiedemann K; Komarova SV
Bone; 2011 Feb; 48(2):202-11. PubMed ID: 20849994
[TBL] [Abstract][Full Text] [Related]
14. Greater magnitude of turnover suppression occurs earlier after treatment initiation with risedronate than alendronate.
Allen MR; Turek JJ; Phipps RJ; Burr DB
Bone; 2011 Jul; 49(1):128-32. PubMed ID: 20637914
[TBL] [Abstract][Full Text] [Related]
15. Quantitative and reliable in vitro method combining scanning electron microscopy and image analysis for the screening of osteotropic modulators.
Grimandi G; Soueidan A; Anjrini AA; Badran Z; Pilet P; Daculsi G; Faucheux C; Bouler JM; Guicheux J
Microsc Res Tech; 2006 Aug; 69(8):606-12. PubMed ID: 16718652
[TBL] [Abstract][Full Text] [Related]
16. Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy.
Sato M; Grasser W
J Bone Miner Res; 1990 Jan; 5(1):31-40. PubMed ID: 2106763
[TBL] [Abstract][Full Text] [Related]
17. High extracellular calcium stimulates osteoclast-like cell formation and bone-resorbing activity in the presence of osteoblastic cells.
Kaji H; Sugimoto T; Kanatani M; Chihara K
J Bone Miner Res; 1996 Jul; 11(7):912-20. PubMed ID: 8797111
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms of action of bisphosphonates: current status.
Roelofs AJ; Thompson K; Gordon S; Rogers MJ
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6222s-6230s. PubMed ID: 17062705
[TBL] [Abstract][Full Text] [Related]
19. Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy.
Leu CT; Luegmayr E; Freedman LP; Rodan GA; Reszka AA
Bone; 2006 May; 38(5):628-36. PubMed ID: 16185944
[TBL] [Abstract][Full Text] [Related]
20. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages.
Luckman SP; Coxon FP; Ebetino FH; Russell RG; Rogers MJ
J Bone Miner Res; 1998 Nov; 13(11):1668-78. PubMed ID: 9797474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
